Wall Street brokerages expect that GenMark Diagnostics, Inc (NASDAQ:GNMK) will post earnings per share (EPS) of ($0.24) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for GenMark Diagnostics’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.17). GenMark Diagnostics reported earnings per share of ($0.27) during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.1%. The company is expected to report its next quarterly earnings report after the market closes on Tuesday, February 27th.
On average, analysts expect that GenMark Diagnostics will report full-year earnings of ($1.18) per share for the current financial year, with EPS estimates ranging from ($1.23) to ($1.11). For the next year, analysts expect that the firm will post earnings of ($0.85) per share, with EPS estimates ranging from ($0.99) to ($0.71). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover GenMark Diagnostics.
Several research analysts have recently weighed in on GNMK shares. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of GenMark Diagnostics in a report on Friday, January 19th. BTIG Research set a $11.00 price objective on shares of GenMark Diagnostics and gave the stock a “buy” rating in a report on Tuesday, January 16th. Cowen reiterated a “buy” rating and set a $10.00 price objective on shares of GenMark Diagnostics in a report on Friday, November 3rd. Canaccord Genuity reiterated a “buy” rating and set a $14.00 price objective on shares of GenMark Diagnostics in a report on Monday, October 30th. Finally, Zacks Investment Research upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $11.80.
GenMark Diagnostics (NASDAQ GNMK) opened at $4.49 on Tuesday. The firm has a market cap of $246.03, a PE ratio of -3.68 and a beta of 0.78. GenMark Diagnostics has a 1-year low of $3.63 and a 1-year high of $13.67. The company has a current ratio of 2.97, a quick ratio of 2.77 and a debt-to-equity ratio of 0.12.
A number of institutional investors and hedge funds have recently bought and sold shares of GNMK. Wrapmanager Inc. increased its position in GenMark Diagnostics by 121.3% during the 4th quarter. Wrapmanager Inc. now owns 39,547 shares of the medical equipment provider’s stock worth $165,000 after purchasing an additional 21,679 shares in the last quarter. UBS Asset Management Americas Inc. increased its position in GenMark Diagnostics by 111.1% during the 4th quarter. UBS Asset Management Americas Inc. now owns 49,400 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 26,000 shares in the last quarter. OLD National Bancorp IN increased its position in GenMark Diagnostics by 120.6% during the 4th quarter. OLD National Bancorp IN now owns 49,765 shares of the medical equipment provider’s stock worth $208,000 after purchasing an additional 27,208 shares in the last quarter. Fairpointe Capital LLC acquired a new stake in GenMark Diagnostics during the 4th quarter worth approximately $220,000. Finally, FDx Advisors Inc. increased its position in GenMark Diagnostics by 124.1% during the 4th quarter. FDx Advisors Inc. now owns 53,689 shares of the medical equipment provider’s stock worth $224,000 after purchasing an additional 29,729 shares in the last quarter.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.